Call Us + 33 1 84 88 31 00

Article R5121-192 of the French Public Health Code

In blood transfusion establishments and in any organisation other than pharmacies, health establishments and health cooperation groups authorised to dispense blood-derived medicinal products, these medicinal products are dispensed on the basis of a named medical prescription. When medicines are dispensed, the information referred to in article R. 5121-187 is recorded in a special register which is listed and initialled by the mayor or police commissioner, or by any other system…

Read More »

Article R5121-193 of the French Public Health Code

When a healthcare professional administers a blood-derived medicinal product outside healthcare establishments or the establishments and organisations mentioned in article R. 5121-192, he/she affixes a detachable label from the immediate packaging of the unit administered to the original prescription kept by the patient. When the medicinal product is administered by a doctor, the latter affixes the other detachable label of the immediate packaging of the unit administered to the medical…

Read More »

Article R5121-196 of the French Public Health Code

When a person authorised to prescribe, dispense or administer medicinal products becomes aware of an adverse reaction which may be due to a blood-derived medicinal product, he/she shall report it immediately, even if he/she has not personally prescribed, dispensed or administered the medicinal product in question. The report must be sent : 1° When the medicinal product has been dispensed in a health establishment or a health cooperation grouping, to…

Read More »

Article R5121-197 of the French Public Health Code

The correspondent mentioned in article R. 5121-181 who receives the report provided for in article R. 5121-196 immediately forwards it to the regional pharmacovigilance centre. If he is otherwise aware of an adverse reaction likely to be due to a blood-derived medicinal product, he shall report it immediately to the regional centre. When adverse reactions are likely to be due to the administration of blood-derived medicinal products to a patient…

Read More »

Article R5121-198 of the French Public Health Code

The regional pharmacovigilance centres inform the Agence nationale de sécurité du médicament et des produits de santé on the same day of the reports of adverse reactions likely to be due to a blood-derived medicinal product that they have received.

Read More »

Article R5121-199 of the French Public Health Code

Organisations or companies exploiting blood-derived medicinal products which have knowledge of adverse reactions likely to be due to these medicinal products inform the Director General of the Agence nationale de sécurité du médicament et des produits de santé under the conditions set out in articles R. 5121-171 to R. 5121-173.

Read More »

Article R5121-200 of the French Public Health Code

Blood establishments and organisations or companies manufacturing or exploiting blood-derived medicinal products which are aware of information likely to cast doubt on the quality of blood or plasma intended for fractionation inform each other. Blood transfusion establishments shall inform the President of the Etablissement Français du Sang. Organisations or companies manufacturing or exploiting medicinal products inform the Agence nationale de sécurité du médicament et des produits de santé. The Agence…

Read More »

Contact a French lawyer now

Contact a French Business Lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.